dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lodise, Thomas P. |
dc.contributor.author | Bassetti, Matteo |
dc.contributor.author | Ferrer Roca, Ricard |
dc.contributor.author | Naas, Thierry |
dc.contributor.author | Niki, Yoshihito |
dc.contributor.author | Paterson, David L. |
dc.contributor.author | Zeitlinger, Markus |
dc.contributor.author | Echols, Roger |
dc.date.accessioned | 2022-09-09T12:53:33Z |
dc.date.available | 2022-09-09T12:53:33Z |
dc.date.issued | 2022-05 |
dc.identifier.citation | Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022 May;20(5):707–19. |
dc.identifier.issn | 1744-8336 |
dc.identifier.uri | https://hdl.handle.net/11351/8120 |
dc.description | Carbapenem resistance; Gram-negative; Cefiderocol |
dc.description.abstract | Introduction
Pathogen-focused, randomized, controlled trials (PF-RCT) are important in the fight against carbapenem-resistant (CR) Gram-negative infections. Some recently approved antibiotics and older generic antibiotics with activity against CR Gram-negative bacteria were investigated in PF-RCTs in a variety of infections.
Areas covered
We searched Pubmed, Cochrane database and international clinical trial databases for PF-RCTs for the period between 2005 and 2020 and compared the study designs, patient populations, infection types, pathogens, and Day-28 all-cause mortality (ACM).
Expert opinion
PF-RCTs are particularly challenging to quantitatively assess and compare due to the heterogeneity in infection types, pathogens, CR mechanism, inclusion/exclusion criteria, and endpoints. Data interpretation is further complicated by lack of formal statistical analysis plans and/or non-inferiority design, and limited power across most PF-RCTs. The studies with new antibiotics (i.e. plazomicin, meropenem/vaborbactam, cefiderocol) ranked lower regarding feasibility, with relatively small sample sizes (analyzed: 37–118) versus the comparative effectiveness studies of older generic drugs (analyzed: 94–406). ACM ranged between 11.8% and 40% for CR Enterobacterales, 17.7% and 57.4% for CR Acinetobacter spp., and 20.0% and 30.8% for CR Pseudomonas aeruginosa. The information gathered must be considered carefully alongside the study limitations and caution should be exercised when making direct comparisons across trials. |
dc.language.iso | eng |
dc.publisher | Taylor & Francis |
dc.relation.ispartofseries | Expert Review of Anti-infective Therapy;20(5) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Malalties bacterianes gramnegatives - Mortalitat |
dc.subject | Medicaments antiinfecciosos |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Gram-Negative Bacterial Infections |
dc.subject.mesh | /mortality |
dc.subject.mesh | Carbapenems |
dc.subject.mesh | Drug Resistance, Microbial |
dc.title | All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1080/14787210.2022.2020099 |
dc.subject.decs | infecciones por bacterias gramnegativas |
dc.subject.decs | /mortalidad |
dc.subject.decs | carbapenems |
dc.subject.decs | farmacorresistencia microbiana |
dc.relation.publishversion | https://doi.org/10.1080/14787210.2022.2020099 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lodise TP] Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA. [Bassetti M] Infectious Diseases Clinic, Department of Health Science, University of Genova and Policlinico San Martino IRCCS Hospital, Genova, Italy. [Ferrer R] Unitat de Cures Intensives, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Naas T] Hôpital Bicetre, Bacteriology-Hygiene Unit, APHP-, University Paris-Saclay, Paris, France. [Niki Y] Division of Clinical Infectious Diseases, Showa University, Tokyo, Japan. [Paterson DL] UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, Australia. [Zeitlinger M] Department of Clinical Pharmacology, Medical University, Vienna, Austria. [Echols R] Infectious Disease Drug Development Consulting, LLC, Easton, CT, USA |
dc.identifier.pmid | 34937518 |
dc.identifier.wos | 000741842700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |